Sun 11/17/2019 19:38 ET
DJIA28004.89224.040.80%TELCO192.541.770.92%GOLD1468.754.700.32%Shanghai2891.3418.500.64%
S&P 5003120.4624.030.77%BANKS495.192.920.59%OIL57.881.111.92%BITCOIN8529.6534.970.41%
NASDAQ8540.8362.350.73%PHARM573.3910.031.75%US/EU1.110.000.00%Futures3115.123.120.10%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Editas Medicine, Inc - EDIT)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add EDIT
  
From: UpAndAway (Rep: 27)Date: 04/30/2019 09:17
Forum: Wall Street Pit - Msg #2784757 - List EDIT msgs Thread #674079013 (Rec: 0)
Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10)

AGN-151587 is set to be the first in vivo, or inside the body, CRISPR-based medicine administered to people anywhere in the world. In the planned Phase 1/2 clinical trial, Allergan and Editas Medicine intend to initiate patient screening mid-year and begin patient dosing in the second half of 2019, enrolling 10-20 patients in the U.S. and Europe.

Sent from my IPhone

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser UpAndAway: Reward | Watch | IgnoreEDIT: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add EDIT
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.